XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating activities:    
Net loss $ (35,605) $ (35,821)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 6,713 5,375
Depreciation 338 519
Loss on sale/disposal of assets 97  
Noncash lease expense 277  
Accretion of premium and discounts on short-term investments (319) 58
Acquired in-process research and development 2,194  
Impairment of capital equipment and right-of-use asset 1,599  
Changes in operating assets and liabilities:    
Prepaid expenses and other current and non-current assets 2,895 1,378
Accounts payable 1,304 (2,052)
Accrued research and development (104) (1,052)
Operating lease liability (380)  
Other current and non-current liabilities (1,888) 95
Net cash used in operating activities (22,879) (31,500)
Investing activities:    
Purchases of property and equipment (308) (488)
Purchases of investments (35,569) (94,570)
Maturity of investments 64,349 105,809
Acquisition of in-process research and development (1,944)  
Proceeds from sale of property and equipment 430  
Net cash provided by investing activities 26,958 10,751
Financing activities:    
Payment of taxes on vested restricted stock units (139)  
Proceeds from exercise of stock options   695
Net cash (used in) provided by financing activities (139) 695
Net increase (decrease) in cash and cash equivalents 3,940 (20,054)
Cash and cash equivalents at beginning of period 13,364 33,418
Cash and cash equivalents at end of period 17,304 13,364
Supplemental disclosure of noncash items:    
Right-of-use asset arising from the adoption of ASC 842 567  
Acquired in process research and development in accrued liabilities $ 250  
Unpaid balance for purchases of property and equipment   $ 115